Management

Thomas Taapken

Ph.D., Executive Chairman

Thomas Taapken joined Imcyse in 2019 as Chairman of the Board after the successful completion of a Series B financing to manage the Company’s transition period and reorganize the management team. Thomas is an independent adviser with over 25 years of experience in the life sciences sector at senior management and board levels. Prior to joining Imcyse, he held executive management positions at several private and publicly listed companies, including Medigene AG, Epigenomics AG and Biotie Therapies Oyj. He has also served on the board of private and public companies such as Scibase AB, Immunic AG and others. He has successfully completed public and private financings, business and M&A transactions and worked in venture capital in both Germany and the U.S. Thomas holds a Ph.D. in Organic Chemistry from the Technical University of Berlin. He also studied economics and physics at the University of Göttingen. 

Marie Gérard

VP Operations & Finance

Marie Gérard joined Imcyse in September 2015 as its corporate affairs manager and was appointed Vice President of Operations and Finance and Secretary to the Board of Directors in January 2020. She has 15 years’ experience supporting the growth of young innovative companies in the life sciences sector. Marie has held executive management positions in another biotech company, KitoZyme. She has supported companies in various roles such as finance management, financing, HR management, communications, administration management, corporate governance, quality assurance and IT. Marie holds a Master’s degree in Business Management from HEC - management school at the University of Liège.  

Antoon Van Oosterhout

Ph.D., VP Research and Development & CSO

Antoon Van Oosterhout was appointed Vice President of Research and Development and Chief Scientific Officer of Imcyse in January 2020. He has more than 25 years’ experience in research and development in the fields of immunology and asthma. Antoon is a guest professor at the University Medical Center of Groningen for Immunology of Lung Diseases. Prior to joining Imcyse, he served as Vice President of GSK’s Allergic Inflammation Discovery Performance Unit until April 2019. Antoon holds a Ph.D. in Immunology from the University of Utrecht

Jean Van Rampelbergh

Ph.D., VP Clinical & Regulatory

Jean Van Rampelbergh was appointed Vice President Clinical and Regulatory in January 2020 after joining Imcyse in March 2016 as Clinical Director and Independent Adviser. He has over 20 years’ experience in clinical trials management. Former Clinical Director at Sanofi Belgium, he held different positions at Janssen Research Foundation, Inserm, Organon, Sanofi-Aventis and Novellas Healthcare. Jean, holds a Ph.D. in Biomedical Sciences from the Faculty of Medicine, University of Brussels (ULB)

Vincent Carlier

Ph.D., R&D Director Immunology

Vincent Carlier has been with Imcyse since its inception. He has been part of the Company’s management team since its foundation dedicated to the development of Imcyse’s technology. Vincent is in charge of R&D management, preclinical research and development, immunology and cellular assays, transversal research and read-outs. Vincent holds a Ph.D. in Biomedical Sciences from the Catholic University of Leuven (KUL), and worked for different departments within KUL as a researcher: the Collen Research Foundation Center for Molecular and Vascular Biology and Life Science Research Partners (LSRP) on the development of the ImotopeTM technology.

Geoffrey Gloire

Ph.D., IP Director

Geoffrey Gloire joined Imcyse in 2016 as IP Director. He is in charge of the protection and valorisation of Imcyse’s intellectual property. Prior to joining the Imcyse team, Geoffrey was a Patent Advisor in Life Sciences at the University of Liège Technology Transfer Office from 2011 until June 2016. He holds a Ph.D. in Molecular Biology from the University of Liège and is a former FNRS Postdoctoral Researcher of the University of Liège  and INSERM in Paris.

Jean Smal

Ph.D., Senior Advisor, Development and Manufacturing

Jean Smal joined Imcyse in September 2015 as Senior Advisor for Development and Manufacturing. He is a senior executive with international experience in research and development and the manufacturing vaccines industry. As Head of Technical Development at GlaxoSmithKline Vaccines, he has gained vast experience in the development of new vaccines with an end-to-end view - from design of antigens to the final commercial production scale. During the last 10 years Jean directly contributed to the development and launch of 12 new vaccines. Prior to GSK, he held various positions from Project Leader to General Manager at Eurogentec CDMO Division (Belgium), a biotech company that offers services for biopharmaceutical product development and production of GMP lots for clinical trials. Jean is a bioengineer and holds a Ph.D. in Biochemistry and a MBA. 

Marcelle Van Mechelen

Ph.D., Senior Scientific Advisor

Marcelle Van Mechelen joined Imcyse in March 2016 as Senior Scientific Advisor. She has over 25 years’ experience in immunology, biotechnology and vaccinology. Marcelle has worked in research and immunology at GSK Vaccines since 1995, and latterly as Vice President Vaccine Research / Research and Preclinical Development from 2012 onwards. She holds a Ph.D. in Immunology from University of Brussels and conducted Postdoc research with the university (1987- 1995) on innate and adaptive immunity.

Luc Vander Elst

R&D Director, In Vivo and Imotope Development

Luc Vander Elst has been part of Imcyse’s management team since its inception and worked for over 20 years on the Company’s technology. He is in charge of research and development management, ImotopeTM design and development as well as preclinical research and development. Luc holds an Engineering degree in Chemistry option Biochemistry and an M.Sc. in Immunology and genetic from the Catholic University of Leuven (KUL), and worked as a researcher for KUL in the Immunology Group of the Center for Vascular and Molecular Biology which is at the origin of Imcyse’s technology